Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Christopher R. Anzalone Ph.D. | Chairman, CEO & President | 2.1M | 1.02M | 1969 |
| Mr. Kenneth A. Myszkowski CPA, CPA, MBA | Chief Financial Officer | 922.63k | -- | 1966 |
| Mr. Patrick O'Brien J.D., PharmD | COO, General Counsel & Secretary | 998.52k | -- | 1964 |
| Dr. James C. Hamilton M.D., MBA | Chief Medical Officer and Head of R&D | 897.69k | -- | 1978 |
| Dr. Mark M. Davis Ph.D. | Founder and Founder & Director of Insert Therapeutics Inc & Calando | -- | -- | -- |
| Dr. Vincent Anzalone CFA | Head of Investor Relations & VP | -- | -- | -- |
| Mr. Howard Lovy | Director of Communications | -- | -- | -- |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist | 486.31k | 5.93M | 1954 |
| Dr. Mark Seefeld | Head of Toxicology & VP | -- | -- | 1954 |
| Aaron Tan | Head of Tax | -- | -- | -- |
Arrowhead Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 609
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Corporate Governance
Upcoming Events
May 7, 2025 at 10:59 AM UTC - May 12, 2025 at 12:00 PM UTC
Arrowhead Pharmaceuticals, Inc. Earnings Date